1 link tagged with all of: openevidence + rag + clinical accuracy
Click any tag below to further narrow down your results
Links
This is the second part of an investigation into whether OpenEvidence, a medical AI company valued at $15B, has technology and content worth that price. The author finds the proprietary AI, content ownership, and accuracy claims all look weak under scrutiny.
- OpenEvidence doesn't own its content; publishers can pull their material at any time, which undercuts the moat a buyer would be paying for.
- Accuracy claims collapse outside exam settings: the company's near-perfect USMLE scores drop to about 27% on real-world clinical cases.
- Ad revenue projections ($400M to $500M in 2026) still put the $15B valuation at 30x to 37.5x a single year of sales, and the company's own CEO now pitches drug discovery as the real prize.